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Aims The aim of this cohort study was to estimate the risk of clinical acute liver
injury among users of oral antifungals identified in the general population of the
General Practice Research Database in UK.
Methods The cohort included 69 830 patients, 20–79 years old, free of liver and
systemic disease, who had received at least one prescription for either oral
fluconazole, griseofulvin, itraconazole, ketoconazole, or terbinafine between 1991
and 1996.
Results Sixteen cases of acute liver injury were identified and validated. Ten cases
occurred during nonuse of oral antifungals with a background rate of 0.6 per
100 000 person-months (95% confidence interval 0.3,1.1). Five cases occurred during
current use of oral antifungals. Two were using ketoconazole, another two
itraconazole, and one terbinafine. Incidence rates of acute liver injury were 134.1
per 100 000 person-months (36.8,488.0) for ketoconazole, 10.4 (2.9–38.1) for
itraconazole, and 2.5 (0.4,13.9) for terbinafine. The remaining case was associated
with past use of fluconazole. Ketoconazole was the antifungal associated with the
highest relative risk, 228.0 (95% confidence interval 33.9,933.0), when compared
with the risk among nonusers, followed by itraconazole and terbinafine with relative
risks of 17.7 (2.6,72.6) and 4.2 (0.2,24.9), respectively.
Conclusions Ketoconazole and itraconazole were the two oral antifungal associated
with a marked increase of clinical acute liver injury. The risk associated with
ketoconazole should be taken into account when prescribing it as initial treatment
for uncomplicated fungal infections.
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Introduction
other systemic antifungals [2, 3]. Some authors have
estimated the incidence to lie between one per 1000 andOral antifungals have been associated with diVerent types
of acute liver injury in a number of case reports and in 3000 patients, after taking into account the eVect of
underreporting in spontaneous monitoring systems [4, 5].several retrospective series. Most of the available data
relate to ketoconazole. Transient asymptomatic changes In a randomized clinical trial, patients with onychomycosis
treated with ketoconazole had a threefold increased riskin liver function tests can appear in 0.5% to 10% of
patients treated with oral antifungals [1]. Clinical liver of developing hepatitis compared with patients treated
with griseofulvin [6]. Several cases of liver injury haveinjury appears to be less frequent, although the vast
majority of data come from cases reported to national been reported in association with griseofulvin [7, 8],
itraconazole [9, 10], and terbinafine [11–14], and mostpharmacovigilance systems.
Published reviews have reported a higher incidence of cases related with fluconazole have occurred in severely
immunodepressed patients [15–20]. In a recent post-
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Table 1 OXMIS codes in case ascertainment.In the present cohort study we estimated the risk of
clinical acute liver injury among users of either oral
OXMIS code Diagnosisfluconazole, griseofulvin, itraconazole, ketoconazole, and
terbinafine identified in the general population of UK
070F Fulminant hepatitis
using the General Practice Research Database (GPRD). 570 Hepatitis/liver necrosis
573 Other liver disorders
5730D Hepatocellular damageMethods
576A Obstructive jaundice
785CP Pale stoolsSource population
7851 Enlarged liver
Methodology used in GPRD has been detailed elsewhere 7852 Jaundice
[22]. GPRD contains clinical computerized information 9779PN Drug-induced jaundice
K501 Liver biopsyentered by general practitioners (GPs) on their patients.
L1151NA Bilirubin serum level abnormalRecorded information includes demographics, details of
L3260AB Abnormal liver function testeach general practitioner visit, a summary of specialists’
L3262AB Biochemical liver dysfunctionclinical notes and hospital letters, results of laboratory
L3263AB Abnormal liver enzymes
tests and a free text section. Prescriptions are directly
L3263H Liver enzymes raised
generated by the computer system with dosage instruc- L3264AB Abnormal hepatic function
tions included. L109H Alanine aminotransferase raised
A validation study with the GPRD has documented L110H Aspartate aminotransferase raised
L1002CR Aspartate aminotransferase level raisedthe recording of medical data in the general practitioners’
computers to be near to complete [23]. Several studies
OXMIS: Oxford Medical Information System.on drug-induced acute liver injury have been published
using the GPRD resource [24]. These studies were able
acute liver injury was defined as a person presenting withto quantify the risk of clinical liver injury associated with
symptoms suggestive of liver disorder (nausea, vomiting,suspected hepatotoxic drugs.
abdominal pain and/or jaundice) referred to a specialist
or admitted to hospital, and who was free of the exclusion
Study cohort criteria. In addition, the following biochemical test results,
based on an international consensus meeting, were aThe study cohort comprised people aged 20–79 years
requisite as part of the case definition of liver injury [25]:who had received at least one prescription for either oral
an increase of more than two times the upper limit offluconazole, griseofulvin, itraconazole, ketoconazole, or
the normal range in alanine aminotransferase (ALT), or aterbinafine between 1 January 1991 and 30 September
combined increase in aspartate aminotransferase (AST),1996. We excluded subjects if they had a history of liver
alkaline phosphatase (APh) and total bilirubin, providedinjury in the preceding 5 years. Subjects with a history
any was more than twice the upper limit of the respectiveof any of the following conditions were also excluded:
normal range. The liver injury was classified as acute ifcancer, liver disease, gallbladder disease, pancreatic disease,
the clinical and laboratory signs had lasted less than 6heart failure, alcohol abuse, HIV infection, rheumatoid
months from the date of onset. The type of liver injuryarthritis, sarcoidosis, systemic lupus or inflammatory
was designated hepatocellular when there was an increasebowel disease. The final study cohort was constituted by
more than twice the upper limit of the normal range in69 830 individuals. We followed these persons from the
ALT alone or R≥5, where R is the ratio of serumdate of first antifungal drug prescription until the earliest
activity of ALT over serum activity of APh. Liver injuryoccurrence of a code for liver injury (Table 1), one of
was designated cholestatic when there was an increase ofthe exclusion conditions mentioned above, age greater
more than twice the upper limit of the normal range inthan 80 years, death or the end of the study period.
APh alone or R≤2. Liver injury was designated mixed
when 2<R<5.
Case ascertainment
We identified 73 patients with a recorded history
Exposure definition
compatible with acute liver injury. We requested from
the general practitioners all clinical records related to Person time at risk was aggregated in three diVerent time
windows according to use of the study antifungal drugs.these events. Case validation was independently performed
by three of the authors (LAGR, BHChS, and AD) Current use encompassed all the days of prescribed
treatment plus an additional period of 14 days at the endwithout knowledge of the exposure status and agreement
was reached on all cases after some discussion. A case of of treatment. Past use was defined as the period of
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90 days following the time window of current use. case status. Fifty patients did not meet the study case
definition and the reasons for exclusion are presented inFinally, the time period starting after past use was defined
as nonuse. We also assessed exposure to a number of Table 3. Most of the patients presented only with minor
elevations of LFTs, or had their LFTs’ derangementsuspected hepatotoxic drugs among the cases [26].
found through routine monitoring. Thus, 16 individuals
met all case definition criteria. Eleven presented with
Analysis
jaundice and four were admitted to a hospital. All cases
recovered from the hepatic injury and none of themIncidence rates of acute liver injury were calculated using
as denominator both the number of patients exposed to resulted in a fatal outcome. Table 4 shows the clinical
and laboratory features of the 16 cases classified accordingeach individual antifungal drug and the corresponding
person-time at risk. Ninety-five percent confidence to their exposure status. Ten cases occurred during
nonuse of oral antifungal drugs corresponding to aintervals were computed on the basis of a Poisson
distribution of case counts within categories of use. The background rate of 0.6 per 100 000 person-months (95%
CI 0.3,1.1). This risk increased considerably with age:Exact program was used to obtain estimates of rate
ratios [27]. 0.4 per 100 000 in persons younger than 60 years and 2.8
per 100 000 in older persons. No material diVerence was
observed between males and females (0.8 vs 0.5 per
Results
100 000 person-months). Half of the cases among
nonusers were exposed to a hepatotoxic drug (Table 4).The study cohort of 69 830 subjects received a total of
149 384 prescriptions. There were marked age and sex Estimates of incidence rate for current use of individual
antifungal drugs are presented in Table 5. Two casesdiVerences among users of the five antifungal drugs with
a higher proportion of women and young patients among occurred during current use of ketoconazole and itracona-
fluconazole and itraconazole users (Table 2). These
diVerences were a consequence of varying leading
indications: candidiasis for fluconazole, itraconazole and
Table 3 Exclusions after review of medical records.
ketoconazole, and onychomycosis for griseofulvin and
terbinafine. The average treatment duration was also Reasons for exclusion Number excluded
variable. Seventy-five percent of fluconazole users and
Minor elevation of liver function tests 2150% of itraconazole users received one single day
Not referred (routine monitoring) 10treatment, respectively. Over 90% of ketoconazole users
Fatty liver disease 6received less than 1 month of therapy. Close to 80% of
Hyperbilirubinemia only 3terbinafine users were treated for 1–3 months.
Alcoholism 3
Griseofulvin users were the group with the longest
Cholelithiasis 3
duration of treatment with one third of patients taking it History of liver disorder 2
for a period longer than 3 months. Infectious mononucleosis 1
We received medical records for 66 patients (90%). In Computer entry error 1
seven subjects, we did not receive information from the Total 50
GPs, or the data received were insuYcient to ascertain
Table 2 Age and sex distribution of the study cohort of users of oral antifungals*.
Fluconazole Griseofulvin Itraconazole Ketoconazole Terbinafine
n (%) n (%) n (%) n (%) n (%)
Sex
Women 33 034 (92) 2931 (44) 15 739 (81) 623 (59) 6279 (47)
Men 2799 (8) 3800 (56) 3749 (19) 429 (41) 7151 (53)
Age (years)
20–39 22 267 (62) 2304 (34) 11 575 (59) 525 (50) 4286 (32)
40–59 10 722 (30) 2937 (44) 6155 (32) 371 (35) 5837 (43)
60–69 1748 (5) 982 (15) 1139 (6) 106 (10) 2122 (16)
70–80 1096 (3) 508 (7) 619 (3) 50 (5) 1185 (9)
Total 35 833 6731 19 488 1052 13 430
*Some of the members of the cohort received more than one antifungal drug during the study period.
© 1999 Blackwell Science Ltd Br J Clin Pharmacol, 48, 847–852 849
L. A. Garcı´a Rodrı´guez et al.
Table 4 Clinical and laboratory findings
and drug exposure of cases of acute liver
injury.
Exposure to Exposure to other
Age oral potentially
(years) Sex* ALT † AP† Pattern‡ antifungals§ hepatotoxic drugs
30 M 3.2 1.0 M Itraconazole No
51 F 4.3 1.7 M Itraconazole Amitriptyline
51 F 7.8 1.2 H Ketoconazole No
63 M 2.6 3.0 C Ketoconazole No
25 F 6.0 11.5 C Terbinafine Chlorpromazine
36 F 30.0 2.0 H Past use No
28 F 17.2 1.4 H Nonuse No
35 F 15.5 1.9 H Nonuse NSAIDs, nifedipine
39 F 3.3 1.0 H Nonuse No
42 F 6.8 1.2 H Nonuse No
48 F 7.2 1.8 M Nonuse Minocycline
50 M 2.1 0.7 M Nonuse No
63 M 10.2 4.0 M Nonuse Phenytoin
65 F 1.8 3.1 C Nonuse Clavulanic acid
67 F 5.7 3.1 C Nonuse Sulfasalazine
69 M 24.3 1.9 H Nonuse No
F=female; M=male; C=cholestatic; H=hepatocellular; M=mixed. †Multiplier of upper
limit of normal value of alanine aminotransferase (ALT) and alkaline phosphatase (AP). ‡Pattern
of liver injury. §Itraconazole, ketoconazole and terbinafine indicate current exposure to these
antifungals. Case with past use had been exposed to fluconazole.
Table 5 Crude incidence rates of acute liver injury among current users of oral antifungals.
Incidence rate
(95% confidence interval )
Per 10 000 Per 100 000 Relative risk*
Antifungal Patients Person-months Cases patients person-months (95% CI)
Fluconazole 35 833 29 701 0 0.0 (0.0, 1.0) 0.0 (0.0, 12.9) 0.0 (0.0, 20.0)
Griseofulvin 6731 35 841 0 0.0 (0.0, 5.5) 0.0 (0.0, 10.7) 0.0 (0.0, 16.5)
Itraconazole 19 488 19 168 2 1.0 (0.1, 3.7) 10.4 (2.9, 38.1) 17.7 (2.6, 72.6)
Ketoconazole 1052 1492 2 19.0 (2.3, 68.7) 134.1 (36.8, 488.0) 228.0 (33.9, 933.0)
Terbinafine 13 430 40 638 1 0.7 (0.02, 4.2) 2.5 (0.4, 13.9) 4.2 (0.2, 24.9)
*Non use person time was used as reference group.
zole, respectively, one case with terbinafine, and no cases under everyday circumstances. Because of the low number
of detected cases, eVect modification by gender or agewere found with current use of fluconazole and griseoful-
vin. All five cases developed during the first month of could not be assessed. Therefore, only crude rates are
presented. When compared to the risk in nonusers, thestarting antifungal treatment. Ketoconazole presented the
greatest absolute risk with an incidence rate of 134 per risk of acute liver injury was markedly increased in users
of ketoconazole and itraconazole, and slightly increased100 000 person-months followed by itraconazole (10.4
per 100 000 person-months) and terbinafine (2.5 per in users of terbinafine. The risk of acute liver injury
among ketoconazole users was the greatest with a relative100 000 person-months). Ketoconazole was the antifungal
drug associated with the greatest relative risk compared risk exceeding 200 compared with nonuse. In view of
the low background risk of idiopathic symptomaticto the background risk among nonusers (Table 5),
followed by itraconazole and terbinafine. hepatic injury in the general population, almost 134 extra
cases occurred per 100 000 person-months of treatment
with ketoconazole. Thus almost 1 in every 500 users of
Discussion
ketoconazole developed acute liver injury. This is higher
than has been estimated in earlier studies with theIn this retrospective cohort study, we assessed the risk of
acute liver injury to antimycotics in a large population exception of one clinical trial [6]. In a recent review of
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